Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines

Infection and Immunity

Volumn 67, Issue 11, 1999, Pages 5841-5847

  Hartman, Antoinette B ^a   Van De Verg, Lillian L ^a,b   Venkatesan, Malabi M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Joint Vaccine Acquisition Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; DRUG FORMULATION; ESCHERICHIA COLI; GUINEA PIG; HOST RESISTANCE; IMMUNOGENICITY; INFECTION PREVENTION; INTRANASAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA FLEXNERI; SHIGELLOSIS; THERMOSTABILITY;

EID: 0032706014     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.11.5841-5847.1999     Document Type: Article

References (36)

1. Alexander, W. A., A. B. Hartman, E. V. Oaks, and M. M. Venkatesan. 1996. Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains. Vaccine 14:1053-1061.
2. Apter, F. M., P. Michetti, L. S. Winner II, J. A. Mack, J. J. Mekalanos, and M. M. Neutra. 1993. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect. Immun. 61:5279-5285.
3. Baqar, S., L. A. Applebee, and A. L. Bourgeois. 1995. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect. Immun. 63:3731-3735.
4. Chong, C., M. Friberg, and J. D. Clements. 1998. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 16:732-740.
5. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, P. K. Neogy, B. F. Stanton, N. Huda, M. U. Khan, B. A. Kay, M. R. Khan, M. Ansaruzzanan, M. Yunus, R. Rao, A. Svennerholm, and J. Holmgren. 1988. Cross protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:372-377.
6. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
7. Covone, M. G., M. Brocchi, E. Palla, W. Dias da Silveira, R. Rappuoli, and C. L. Galeotti. 1998. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect. Immun. 66:224-231.
8. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
9. Dickinson, B. L., and J. D. Clements. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant, p. 73-87. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, San Diego, Calif.
10. Elson, C. O. 1996. Cholera toxin as a mucosal adjuvant, p. 59-72. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, San Diego, Calif.
11. Hale, T. L. 1995. Shigella vaccines, p. 179-204. In D. A. A. Ala'Aldeen and C. E. Hormaeche (ed.), Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons, Inc., New York, N.Y.
12. Harokopakis, E., G. Hajishengallls, T. E. Greenway, M. W. Russell, and S. M. Michalek. 1997. Mucosal immunogenicity of a recombinant Salmonella typhimurium cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits. Infect. Immun. 65:1445-1454.
13. Hartman, A., L. Van De Verg, N. Bendiuk, and H. Collins. 1993. Oral immunization of guinea pigs with and without cholera toxin as adjuvant protects against ocular challenge with Shigella, abstr. E-102, p. 160. In Abstracts of the General Meeting of the American Society for Microbiology 1993. American Society for Microbiology, Washington, D.C.
14. Hartman, A. B., L. L. Van De Verg, H. H. Collins, Jr., D. B. Tang, N. O. Bendiuk, D. N. Taylor, and C. J. Powell. 1994. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect. Immun. 62:412-420.
15. Holmgren, J., H. Lindblad, P. Fredman, L. Svennerholm, and A. Myrvold. 1985. Comparison of receptors for cholera and Escherichia coli enterotoxin in human intestine. Gastroenterology 89:27-35.
16. Institute of Medicine. 1986. The prospect for immunizing against Shigella spp., p. 329-337. In New vaccine development: establishing priorities, vol. 2. Diseases of importance in developing countries. National Academy Press, Washington, D.C.
17. Katz, J. M., X. Lu, S. A. Young, and J. C. Galphin. 1997. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175:352-363.
18. Kotloff, K. L., D. A. Herrington, T. L. Hale, J. W. Newland, L. L. Van De Verg, J. P. Cogan, P. J. Snoy, J. C. Sadoff, S. B. Formal, and M. M. Levine. 1992. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 60:2218-2224.
19. Lamm, M. E., J. G. Nedrud, C. S. Kaetzel, and M. B. Mazanec. 1996. New insights into epithelial cell function in mucosal immunity: neutralization of intracellular pathogens and excretion of antigens by IgA, p. 141-148. In M. F. Kagnoff and H. Kiyono (ed.), Essentials of mucosal immunology. Academic Press, Inc., New York, N.Y.
20. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308.
21. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P, Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dougan, R. Rappuoli, and P. Ghiara. 1998. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16:33-37.
22. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 15:4621-4629.
23. Mestecky, J. 1987. The common mucosal system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7:265-276.
24. Michetti, P., M. J. Mahan, J. M. Slauch, J. J. Mekalanos, and M. R. Neutra. 1992. Monoclonal secretory immunoglobulin protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect. Immun. 60:1786-1792.
25. Newland, J. W., T. L. Hale, and S. B. Formal. 1992. Geneotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K-12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766-776.
26. Ogra, P. L., Y. Chiba, K. R. Beutner, and A. Morag. 1976. Vaccination by non-parenteral routes: characterization of immune response. Dev. Biol. Stand. 33:19-26.
27. Partidos, C. D., M. Pizza, R. Rappuoli, and M. W. Steward. 1996. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology 89:483-487.
28. Pizza, M., M. Domenighini, W. Hoi, V. Gianelli, M. R. Fontana, M. M. Giuliani, C. Magagnoli, S. Peppoloni, R. Manetti, and R. Rappuoli. 1994. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14:51-60.
29. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
30. Svennerholm, A. M., L. A. Hanson, J. Holmgren, B. S. Lindblad, B. Nilsson, and F. Quereshi. 1980. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect. Immun. 30:427-430.
31. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627-635.
32. Taylor, D. N., D. F. Philip, M. Zapor, A. Trofa, L. Van De Verg, A. Hartman, N. Bendiuk, J. W. Newland, S. B. Formal, J. C. Sadoff, and T. L. Hale. 1994. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2. Vaccine 12:565-568.
33. Walker, R. I., and J. D. Clements. 1993. Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization. Vaccine Res. 2:1-10.
34. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharide extraction with phenol:water and further application of the procedure. Methods Carbohydr. Chem. 5:83-91.
35. Wetzin, R., H. Kleanthous, F. Guirakhoo, T. P. Monath, and C. K. Lee. 1997. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 15:370-376.
36. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 15:4115-4121.